A/Prof Sumitra Ananda
Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology
130 Scholarly works
2 Projects
HIGHLIGHTS
2026
Journal article
GOG-3119/ENGOT-en29/TroFuse-033: A phase 3, randomized study of sacituzumab tirumotecan plus pembrolizumab vs pembrolizumab alone as first-line maintenance therapy for mismatch repair-proficient endometrial cancer
DOI: 10.1016/j.ygyno.2026.01.1682026
Journal article
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study
DOI: 10.1016/S0140-6736(26)00602-12026
Journal article
Abstract CT304: Narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel in first-line patients with advanced pancreatic cancer (ACCENT trial) a Phase 1b 2a study-Interim analysis
DOI: 10.1158/1538-7445.am2026-ct3042023
Research grants (other domestic)
REZOLV3R: Randomised Trial of Palliative Intraperitoneal Bevacizumab Following Therapeutic Drainage of Recurrent Malignant Ascites in Patients With Chemotherapy Resistant Solid Tumours
2021
Research Grant
HyNOVA - A Randomised Study Comparing Hyperthermic and Normothermic Intraperitoneal Chemotherapy Following Interval Cytoreductive Surgery for Stage III Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer
2018
Journal article
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
DOI: 10.1038/s41467-018-05564-z2014
Journal article
Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts
DOI: 10.1016/j.molonc.2014.01.008
RECENT SCHOLARLY WORKS
2026
Journal article
Azenosertib in combination with bevacizumab as maintenance therapy in patients with advanced ovarian cancer: part 2 of a phase 1b study
DOI: 10.1016/j.ijgc.2026.1046112026
Journal article
Narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel as first-line treatment for patients with metastatic pancreatic cancer (ACCENT trial): Phase 2a results.
DOI: 10.1200/jco.2026.44.2_suppl.7352025
Journal article
SAFETY OF HYPERTHERMIC VERSUS NORMOTHERMIC INTRAPERITONEAL CHEMOTHERAPY FOLLOWING INTERVAL CYTOREDUCTIVE SURGERY FOR STAGE III EPITHELIAL OVARIAN CANCER
DOI: 10.1016/j.ijgc.2025.1021642025
Journal article
LBA3 Pembrolizumab vs placebo plus weekly paclitaxel ± bevacizumab in platinum-resistant recurrent ovarian cancer: Results from the randomized double-blind phase III ENGOT-ov65/KEYNOTE-B96 study
DOI: 10.1016/j.annonc.2025.09.0492025
Journal article
1222TiP TroFuse-022/ENGOT-ov84/GOG-3103 part 1: A phase III study of sacituzumab tirumotecan (Sac-TMT) ± bevacizumab (Bev) maintenance therapy vs standard of care (SoC) after second-line (2L) platinum-based doublet chemotherapy (chemo) for platinum-sensitive recurrent ovarian cancer (PSROC)
DOI: 10.1016/j.annonc.2025.08.18572025
Conference Proceedings
1221TiP GOG-3119/ENGOT-en29/TroFuse-033: A phase III, randomized study of sacituzumab tirumotecan (sac-TMT) pembrolizumab (pembro) vs pembro alone as first-line (1L) maintenance therapy for mismatch repair-proficient (pMMR) endometrial cancer (EC)
DOI: 10.1016/j.annonc.2025.08.18562025
Journal article
Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial
DOI: 10.1038/s41591-025-03579-w